- WuXi Biologics ranked top in its industry with a Top 1% S&P Global CSA Score.
- 848 companies from 59 industries were included in the S&P Global Sustainability Yearbook 2026.
- WuXi Biologics supports 945 client projects, including 74 in Phase III and 25 in commercial manufacturing.
- The company employs over 12,000 people across China, the US, Ireland, Germany, Singapore, and Qatar.
Recognition in Sustainability
WuXi Biologics has been included in the S&P Global Sustainability Yearbook 2026, marking its fourth consecutive year of recognition. The company achieved a Top 1% S&P Global CSA Score, ranking it at the top of its industry.
Industry-Wide Assessment
The Yearbook highlights companies with strong corporate sustainability performance based on their S&P Global 2025 CSA Score. Out of over 9,200 companies assessed, only 848 across 59 industries were selected for inclusion.
Commitment to ESG
WuXi Biologics is committed to enhancing sustainability performance, as reflected in its participation in initiatives like the United Nations Global Compact and the Pharmaceutical Supply Chain Initiative. The company has received numerous accolades, including an MSCI AAA Rating, EcoVadis Platinum Medal, and inclusion in the Dow Jones Sustainability Indices.
Global Operations
With over 12,000 employees in multiple countries, WuXi Biologics supports 945 integrated client projects, including 74 in Phase III and 25 in commercial manufacturing. The company leverages advanced technologies and clean-energy sources to drive its ESG strategy.
